1. Home
  2. IMCR vs TRS Comparison

IMCR vs TRS Comparison

Compare IMCR & TRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

N/A

Current Price

$26.33

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Logo TriMas Corporation

TRS

TriMas Corporation

N/A

Current Price

$36.95

Market Cap

1.3B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
IMCR
TRS
Founded
2008
1986
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Specialties
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2016
2004

Fundamental Metrics

Financial Performance
Metric
IMCR
TRS
Price
$26.33
$36.95
Analyst Decision
Buy
Buy
Analyst Count
12
2
Target Price
★ $59.30
$45.00
AVG Volume (30 Days)
414.0K
★ 430.4K
Earning Date
11-06-2026
10-29-2026
Dividend Yield
N/A
★ 0.42%
EPS Growth
★ 30.39
N/A
EPS
N/A
★ 22.64
Revenue
$249,428,000.00
★ $645,720,000.00
Revenue This Year
$9.28
$5.16
Revenue Next Year
$9.91
$1.55
P/E Ratio
★ N/A
$1.67
Revenue Growth
★ 43.05
N/A
52 Week Low
$26.53
$31.67
52 Week High
$40.71
$45.43

Technical Indicators

Market Signals
Indicator
IMCR
TRS
Relative Strength Index (RSI) 32.57 41.01
Support Level N/A $35.40
Resistance Level $31.75 $37.53
Average True Range (ATR) 1.46 1.25
MACD -0.46 -0.12
Stochastic Oscillator 9.12 23.00

Price Performance

Historical Comparison
IMCR
TRS

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About TRS TriMas Corporation

TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.

Share on Social Networks: